IL1B and melanoma: In this context, Lee et al. showed that repeated administration of IL-1β improves the antitumor activity of ATCT in a mouse model of melanoma, while Sarkar et al. found that IL-1 supplementation enhances priming and expansion of anti-CD19 human CAR-T cells (241, 245).